Sector News

Amgen puts out welcome mat for Celgene’s Otezla reps, but will they join?

August 29, 2019
Life sciences

Amgen is ponying up $13.4 billion for Celgene’s psoriasis blockbuster Otezla. But it’s not just getting the drug—it’s also picking up the 800 to 900 Celgene employees who work on Otezla. And some Otezla sale reps are worried.

Amgen says it looks forward to welcoming everyone who works on Otezla to the Amgen team to “continue their important work” in psoriasis and other immunologic diseases.

“The Otezla team has done a world class job of building and growing Otezla over time. We expect that approximately 800-900 Celgene employees primarily dedicated to Otezla, including sales reps, will transfer to Amgen,” an Amgen spokeperson said via email.

Amgen declined to say how many of the total number of Otezla workers are sales reps, and Celgene referred questions back to Amgen.

Yet with the final sale months still away, both the Celgene and Amgen rumor mills are working overtime with concerned sales reps speculating about what happens next for them.

Some Celgene sales rep commenters on CafePharma are worried about losing their jobs or their severance packages.

One lamented, “My sense is that Amgen won’t keep us. They have a division calling on Dermatologist with Enbrel. It’s too many reps too much overlap. We are toast!” Another wrote, “My concern is if Amgen keeps us, but then raises our quotas soon after. We can’t get the severance for not meeting numbers.”

Under the Bristol-Myers Squibb acquisition of Celgene, which is the agreement the reps would have been under had the Federal Trade Commission not forced Celgene to sell off Otezla as part of the bigger deal, people whose jobs are eliminated as a result of the merger are set to receive specific benefits. According to documents filed with the SEC, it’s a minimum of six months base pay and a 50% target bonus for full-time and part-time employees not covered by another severance plan.

However, the Otezla reps are no longer under that plan. Since the new Amgen deal was just announced, detailed provisions such as those are still being determined.

One Amgen board commenter on CafePharma said that it would be a good move by Amgen to take most of the Otezla reps.

“Like any sales force, there are some good, some average and some bad. My sense from interacting with them is that they have many more good and very few bad,” the person wrote.

By Beth Snyder Bulik

Source: Fierce Pharma

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.